Intelligence · Patents
Patents expiring in 2039
Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.
- Patents
- 1,782
Quick answer
1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10253024
Polycyclic indoline and indolenine compounds
granted -
US 10253294
Galactose oxidase treatment of dendritic cells to improve their immunogenicity
granted -
US 10253054
Prodrugs of pyridone amides useful as modulators of sodium channels
granted -
US 10253044
9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors
granted -
US 10252997
Monocyclic compound
granted -
US 10251955
Heparin-mimicking sulfonated reverse thermal gel for the delivery of heparin-binding therapeutic proteins
granted -
US 10252039
Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
granted -
US 10252974
Cationic lipid
granted -
US 10251959
Oligomer-beta blocker conjugates
granted -
US 10251914
Compositions and methods for transplantation of colon microbiota
granted -
US 10251912
MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
granted -
US 10251909
Potassium-magnesium citrate as a surrogate of the DASH diet in managing hypertension
granted -
US 10251923
Therapeutic uses of mastic gum fractions
granted -
US 10251896
Compositions for improving cell viability and methods of use thereof
granted -
US 10251881
Particulate materials
granted -
US 10251851
Bicyclic analgesic compounds
granted -
US 10251874
Crystalline forms of a JAK inhibitor compound
granted -
US 10251398
Improving shelf life and color profile of resin compositions with silver nanoparticles
granted -
US 10258612
Mitochondrial lipid permeable iron chelators for treating and preventing ischemia/reperfusion (I/R) injury in the heart following an ischemic event
granted -
US 10259870
Anti-ANGPTL8 antibodies and uses thereof
granted -
US 10261095
Predictive biomarkers of clinical response to anti-LPS immunoglobulin treatment
granted -
US 10258573
Micronized insulin and micronized insulin analogues prepared under acidic conditions, and methods of manufacturing the same under acidic conditions
granted -
US 10258582
Nicotinic receptor non-competitive antagonists
granted -
US 10258627
DNA-PK inhibitors
granted -
US 10258686
Materials and methods for respiratory disease control in canines
granted -
US 10260069
Selective antisense compounds and uses thereof
granted -
US 10261083
Compositions and methods for detecting protease activity in biological systems
granted -
US 10259780
Treatment of cataplexy
granted -
US 10260054
Engineered organophosphorus acid anhydrolases and methods of use thereof
granted -
US 10261094
Competitive ligand binding assay for detecting neutralizing antibodies
granted -
US 10260101
C-kit oncogene mutations in melanoma
granted -
US 10259846
Bouvardin derivatives and therapeutic uses thereof
granted -
US 10259845
Peptides whose uptake by cells is controllable
granted -
US 10259826
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
granted -
US 10259824
Complement C3d-binding compounds
granted -
US 10259786
Psychotropic agents and uses thereof
granted -
US 10259781
Imaging agents
granted -
US 10258699
Angiopep and derivatives thereof for imaging amyloids
granted -
US 10258701
Labeled evans blue dye derivative for in vivo serum albumin labeling
granted -
US 10258655
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 10258682
Attenuated chlamydia vaccine
granted -
US 10258678
Indoleamine 2,3-dioxygenase based immunotherapy
granted -
US 10258635
Formulations and compositions of vitamin D analogs for treating and preventing cancer and other diseases
granted -
US 10258631
Formulations of testosterone and methods of treatment therewith
granted -
US 10258630
Vaginal inserted estradiol pharmaceutical compositions and methods
granted -
US 10258629
Liposomal drug encapsulation
granted -
US 10258606
Endothelin single nucleotide polymorphisms and methods of predicting β-adrenergic receptor targeting agent efficacy
granted -
US 10258613
Compositions for treating retinal degeneration and methods of production and use thereof
granted
Frequently asked questions
How many pharma patents expire in 2039?
1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.